Fewer new lesions, side effects differentiate fingolimod from dimethyl fumarate

VANCOUVER – Multiple sclerosis patients discontinued treatment and relapsed earlier with dimethyl fumarate (Tecfidera) than with fingolimod (Gilenya), and had more gadolinium-enhancing lesions at 12...
Source: Clinical Neurology News - Category: Neurology Source Type: news